Acorda Therapeutics said Monday that it will stop work on an experimental treatment for Parkinson’s disease, spelling the end for a drug the Ardsley, NY, company added to its pipeline last year in a $363 million deal. The announcement follows the recent emergence of safety problems for the Acorda (NASDAQ: ACOR) drug, tozadenant. Acorda said […]
NYS Entity Status
NYS Filing Date
FEBRUARY 07, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - A & J DRUGS INC
Around the Web
- Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another
By Frank Vinluan - Monday Nov 20, 2017
- A Drug Maker Spends Big in Washington to Make Itself Heard
By JAY HANCOCK, ELIZABETH LUCAS and SYDNEY LUPKIN - Friday Jul 21, 2017
Mallinckrodt’s spending on political donations and lobbying comes as the drug industry as a whole beefs up its Capitol Hill presence.
- Ryder Trucks Launches Campaign With 'Inc.'
Tuesday Sep 19, 2017
"The campaign underscores how truck owners are essentially dumping cash all over America's highways from all the hidden costs required in maintaining a private fleet," Ryder's Karen Jones tells"Marketing Daily."
- For Parkinson’s, Two New Drugs Coming As Prevail Gets Started in NY
By Ben Fidler - Wednesday Aug 9, 2017
A drug that actually slows or reverses the brain damage inflicted by Parkinson’s disease, rather than just alleviates its often debilitating symptoms, remains elusive. But Prevail Therapeutics, a startup just launched in New York, has become the latest to try. This morning, the Silverstein Foundation, a nonprofit organization formed by OrbiMed partner Jonathan Silverstein, announced […]
- Samsung Releases Lower-Cost Alternative to J&J's Drug Remicade
Monday Jul 24, 2017
South Korea’s Samsung conglomerate, best known for its smartphones and televisions, will make available on Monday in the U.S. its lower-price copy of Johnson & Johnson’s blockbuster rheumatoid-arthritis drug Remicade
- Amid Opioid Crisis, Insurers Restrict Pricey, Less Addictive Painkillers
By KATIE THOMAS and CHARLES ORNSTEIN - Monday Sep 18, 2017
Drug companies and doctors have been accused of fueling the opioid crisis, but some question whether insurers have played a role, too.